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OBJECTIVES The purpose of this study was to assess the long-term value of pharmacologic stress
echocardiography with either dipyridamole or dobutamine (DET) for prediction of cardiac
death in patients with proven or suspected coronary artery disease (CAD).
BACKGROUND Stress echocardiography is an established, cost-effective technique for the detection of CAD.
METHODS From the Echo Persantine International Cooperative–Echo Dobutamine International
Cooperative data bank, 7,333 patients (5,452 males; 59 10 years) underwent pharmacologic
stress echocardiography with either high-dose dipyridamole (0.84 mg/kg over 10 min) (n 
4,984) or high-dose dobutamine (up to 40 g/kg/3 min) (n 2,349) for diagnostic purposes.
Patients were followed up for a mean of 2.6 years (range 1 to 206 months).
RESULTS The DET was positive for myocardial ischemia in 2,854 (35%) patients and negative in 4,479
(61%) patients. During the follow-up there were 161 cardiac deaths (sudden death and fatal
myocardial infarction) (2.1% of the total population). Kaplan-Meier survival estimates
showed a significantly better outcome for those patients with a negative pharmacologic stress
echocardiography test compared with those with a positive test (92 vs. 71.2%, p  0.0000).
CONCLUSIONS Pharmacologic stress echocardiography with either dipyridamole or dobutamine is effective in
predicting cardiac death during a long-term follow-up. A negative stress echocardiography
test result is related to a favorable outcome. (J Am Coll Cardiol 2003;41:589–95) © 2003
by the American College of Cardiology Foundation
Pharmacologic stress echocardiography is an established,
cost-effective technique for the detection of coronary artery
disease (CAD) (1). According to the American College of
Cardiology/American Heart Association guidelines, phar-
macologic stress echocardiography with either dobutamine
or dipyridamole (DET) is a class I indication (of docu-
mented effectiveness and usefulness) for the diagnosis of
CAD and for the prognostic stratification of patients with
known CAD (2,3). The widespread use in clinical practice
has become possible only after evidence collected through
large-scale, multicenter studies that demonstrated its feasi-
bility, safety, and diagnostic and prognostic accuracy (4–8).
All-cause and cardiac death are the most clinically mean-
ingful prognostic end points (9–11). The purpose of this
study was to assess the long-term value of DET for
prediction of cardiac death in patients with known or
suspected CAD in a large-scale, multicenter, observational,
and prospective study design on the basis of evidence
collected by 35 different echocardiographic laboratories.
PATIENTS AND METHODS
From the Echo Persantine International Cooperative–Echo
Dobutamine International Cooperative and Institute of
Clinical Physiology data bank, between 1985 and 2000,
7,599 prospectively enrolled consecutive patients with
known or suspected CAD performed a DET test and
entered a follow-up program. A total of 266 patients (3%)
were lost to follow-up; therefore, the final population
consisted of 7,333 patients (5,452 males, mean age 59  10
years). The most common indication for testing was risk
evaluation after infarction (29%); 2,737 (37%) had a test
performed for the evaluation of chest pain. Known CAD
was present in 2,696 (37%) patients, reflecting previous
myocardial infarction in 29% and revascularization in 6%.
Risk factors were highly prevalent, with 30% of the patients
having hypertension and 40% hypercholesterolemia. The
pretest likelihood of CAD was estimated from age, gender,
and symptoms (12); patients with known CAD were as-
signed a value of 100%. The estimated likelihood of CAD
was less than 50% in 849 patients (11.5.%), 50% to 80% in
2,556 patients (34.8%), and greater than 80% in 3,928
patients (53.6%). According to individuals needs and phy-
sician’s choices, 5,542 patients were evaluated after antian-
ginal drugs had been discontinued, and 1,791 patients were
evaluated during antianginal treatment (nitrates and/or
calcium antagonists and/or beta-blockers).
Stress protocols. Two-dimensional echocardiography and
12-lead electrocardiographic (ECG) monitoring were per-
formed in combination with either high-dose dipyridamole
(up to 0.84 mg over 10 min) or high-dose dobutamine (up
to 40 g/kg body weight per min with coadministration of
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atropine up to 1 mg), according to well-established proto-
cols (3). During the procedure, blood pressure and the ECG
were recorded each minute. Low-dose positivity was con-
sidered to have occurred during the dose of 0.56 mg/kg in
4 min of dipyridamole or during the following 4 min or at
the dose 20 g/kg/min of dobutamine. Quality control of
stress echo performance and reading in enrolled centers was
previously described in depth (5). Briefly, the reader from
each recruiting center met the predefined criteria for stress
echo reading. At that point, the center could start recruiting
patients and reading of stress echo from the recruiting
center was directly entered in the data bank.
Follow-up data. By inclusion criteria, follow-up data were
obtained in all patients. Cardiac and total mortality were the
primary end points; hospital and physician records and
death certificates were used to ascertain the cause of death,
which was attributed to a cardiac etiology if a cardiac illness
provoked the final presentation or if death was sudden and
unexpected. For the analysis of cardiac mortality, patients
dying from other causes were censored from follow-up at
the time of death. Coronary bypass surgery or coronary
angioplasty was not identified as a cardiac event, and
patients were censored at the time of these procedures.
Statistical analysis. The statistical analyses included de-
scriptive statistics (frequency and percentage of categorical
variables and mean and standard deviation of continuous
variables), Kaplan-Meier survival curves, and Cox propor-
tional hazards models. Differences between survival curves
were compared with the log-rank test. All analyses were
performed using SPSS statistical software (SPSS Inc.,
Chicago, Illinois), and p values0.05 were considered to be
statistically significant. Receiver-operating characteristics
analysis was used to determine the optimal cutoff value for
prediction of cardiac death with respect to the variation of
wall motion score index (WMSI) and the number of
ischemic segments during the test. The best cutoff value was
defined as the point with the highest sum of sensitivity and
specificity.
RESULTS
The main clinical and echocardiographic data are reported
in Table 1.
Follow-up data. Patients were followed for a mean of 2.6
 3 years. The total mortality was 336 individuals (4.5%),
among whom death was attributed to cardiac causes in 161
(2.1%). Myocardial revascularization was performed in
2,077 patients who were censored from follow-up at this
time.
Cardiac and total mortality. Considering cardiac mortal-
ity, there were 80 events in patients with a positive test
versus 81 events in patients with a negative test (2.8% vs.
Table 2. Univariate Predictors of Total and Cardiac Mortality
Cardiac Mortality Total Mortality
RR (95% CI) p Value RR (95% CI) p Value
Age 1.05 (1.03–1.06) 0.0000 1.06 (1.05–1.07) 0.0000
Male gender 1.7 (1.21–2.6) 0.0032 1.4 (1.13–1.8) 0.0030
Hypertension 1.2 (1.0–1.5) 0.0495
Previous non–Q-wave MI 1.8 (1.14–2.8) 0.0107 1.6 (1.18–2.2) 0.0030
LBBB 2.3 (1.3–4.2) 0.0039 1.68 (1.04–2.7) 0.0321
Previous Q-wave MI 2.5 (1.8–3.4) 0.0000 1.6 (1.32–2.09) 0.0000
Test positivity 2.2 (1.6–3.1) 0.0000 2.09 (1.68–2.5) 0.0000
Rest WMSI 5.8 (4.2–8.1) 0.0000 3.8 (3.01–4.9) 0.0000
Peak WMSI 6.0 (4.4–8.1) 0.0000 4.02 (3.2–5.0) 0.0000
CI  confidence interval; LBBB  left bundle-branch block; MI  myocardial infarction; RR  relative risk; WMSI  wall
motion score index.
Abbreviations and Acronyms
CAD  coronary artery disease
CI  confidence interval
DET  pharmacologic stress echocardiography with
either dobutamine or dipyridamole
ECG  electrocardiograph/electrocardiographic
RR  relative risk
WMSI  wall motion score index
Table 1. Rest and Stress Findings in the Study Population
No. of patients 7,333





History of angina 2,737 (37%)
Left bundle-branch block 239 (3.3%)
Previous myocardial infarction 2,153 (29%)
Previous coronary revascularization 453 (6.1%)
Dobutamine stress echo 2,349 (32%)
Dipyridamole stress echo 4,984 (68%)
Positive DET 2,854 (39%)
Wall motion score index at rest 1.3  0.4
Wall motion score index at peak stress 1.4  0.4
ECG changes during DET 2,631 (36%)
Chest pain during DET 1,807 (25%)
Test performed on antianginal therapy 1,791 (24.4%)
Coronary angiography 4,037
Normal coronary artery disease 546
1-vessel disease 1,459
2- and 3-vessel disease 2,032
DET  dipyridamole or dobutamine stress echocardiography; ECG  electrocar-
diographic.
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Figure 1. Kaplan-Meier survival curves (considering cardiac death as an end point) in patients with presence (DET) and absence (DET) of myocardial
ischemia at pharmacologic stress echocardiography. Survival is worse in patients with inducible ischemia.
Figure 2. Kaplan-Meier survival curves (considering total mortality as an end point) in patients with presence (DET ) and absence (DET ) of
myocardial ischemia pharmacologic stress echocardiography. Survival is worse in patients with inducible ischemia.
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1.81%, p  0.0046). Univariate predictors of cardiac death
and total mortality are reported in Table 2. Using Cox’s
proportional hazards model, age (relative risk [RR] 1.05,
95% confidence interval [CI] 1.03 to 1.06), previous
Q-wave myocardial infarction (RR 1.44, 95% CI 1.02 to
2.03), previous non–Q-wave myocardial infarction (RR
1.81, 95% CI 1.02 to 2.03), and peak WMSI (RR 5.1, 95%
CI 3.6 to 7.03) were independent predictors of cardiac
death. Kaplan-Meier survival estimates for cardiac mortality
and total mortality are reported in Figures 1 and 2. Delta
WMSI is highly predictive of cardiac death in patients with
a positive stress test (Fig. 3). In Figure 4, the cumulative
survival rates in patients with stress test positivity stratified
according to pharmacologic dose infused is reported (p 
0.0000 between high-dose and low-dose positivity). When
clinically, realistic sequential models for the prediction of
cardiac mortality were used, stress echocardiography showed
incremental value versus clinical evaluation and resting left
ventricular function identified by the rest WMSI (Fig. 5).
The same was found for total mortality (Fig. 6).
Stress echo results and coronary angiography. The prog-
nostic value of pharmacologic stress echocardiography rela-
tive to coronary angiography was addressed in a subgroup of
4,037 patients who also underwent coronary angiography
within a year of the pharmacologic stress echocardiography
without an intervening procedure. Of these individuals, 546
had no significant CAD, 1,459 had single-vessel disease,
and 2,032 had multivessel coronary disease. With an inter-
active procedure, we analyzed the predictivity of the model
for cardiac death considering the variables in clinical order:
clinical variable first, stress echocardiographic parameters,
and coronary angiography. Coronary angiography parame-
ters did not add significant predictive power to the model
compared with stress echocardiographic variables (Fig. 7).
DISCUSSION
In patients with known or suspected CAD, DET is an
independent predictor of cardiac death, incremental to other
parameters. The addition of coronary angiographic data
added little prognostic power to the results of stress echo-
cardiography.
Comparison with previous studies. Previous studies have
demonstrated that the extent of inducible ischemia evi-
denced at stress echocardiography is related to outcome
(5–8,10,11,13–22). The major merit of the present study is
the sample size, consisting of 7,333 patients, large enough
to provide prognostic information only analyzing hard end
points such as total and cardiac mortality, with no need to
include surrogate or composite end points in order to
increase the power of prognostication.
Figure 3. Kaplan-Meier survival curves (considering death as an end point) in patients with a positive pharmacologic stress echo test separated on the basis
of the extent of the inducible ischemia identified by the delta wall motion score index (WMSI) set at 0.37. The survival is worse for larger variations of
WMSI; Delta WMSI 0.37 versus Delta WMSI 0.37.
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Limitations of the study. The results of the test, available
to the referring physicians, might have influenced the
clinical management of the patients, especially regarding
coronary revascularization, but this might have only lowered
the prognostic power of the test, as patients were censored
at the time of the procedure.
Figure 4. Kaplan-Meier survival curves (considering cardiac death) in patients stratified according to DET test results in relation to the pharmacologic dose
achieved. Low-dose positivity was considered to have occurred during the dose of 0.56 mg/kg in 4 min of dipyridamole or during the following 4 min or
at the dose 20 g/kg/min of dobutamine (high-dose positivity vs. low-dose positivity, p  0.0000).
Figure 5. Bar graph showing global chi-square value of significant predictor modeling of cardiac mortality according to an interactive procedure. In the
model, stress echocardiographic parameters still added significant information to clinical variables and rest echocardiographic parameters. WMSI  wall
motion score index.
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Clinical implications. Patients with a negative stress echo
are at very low risk for death (1%/year). It is very difficult
to demonstrate that even the most aggressive treatments
might lower this rate of death. These patients can be treated
medically without referral to coronary angiography (21),
because the practice of performing anatomy-driven coronary
revascularization in the absence of inducible ischemia is a
frequent but nonrecommended therapeutic option (23). In
patients with positive stress echo, coronary angiography is
warranted and ischemia-driven revascularization can have
maximal beneficial prognostic effects (21,24). The more
severe the inducible ischemia (i.e., the higher the rest stress
variation in WMSI or the lower the dose achieved), the more
urgent is the indication for ischemia-driven revascularization.
Figure 6. Bar graph showing global chi-square value of significant predictor modeling of total mortality according to an interactive procedure. In the model,
stress echocardiographic parameters still added significant information to clinical variables and rest echocardiographic parameters. WMSI  wall motion
score index.
Figure 7. Bar graph showing incremental value of pharmacologic stress echocardiography results to clinical characteristics and coronary angiography for
prediction of cardiac outcome in 4,037 patients who underwent pharmacologic stress echocardiography and coronary angiography. WMSI  wall motion
score index.
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